Methenmadinone acetate
| Clinical data | |
|---|---|
| Trade names | Superlutin, Antigest |
| Other names | Superlutin; Superlutine; MMA; Methylenedehydroacetoxyprogesterone; MDAP; 17α-Hydroxy-16-methylene-δ6-progesterone 17α-acetate; 17α-Acetoxy-16-methylenepregna-4,6-diene-3,20-dione |
| Routes of administration |
By mouth |
| Drug class | Progestogen; Progestin; Progestogen ester |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C24H30O4 |
| Molar mass | 382.500 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Methenmadinone acetate (MMA), also known as methylenedehydroacetoxyprogesterone (MDAP) and sold under the brand names Superlutin and Antigest, is a progestin medication which was developed in Czechoslovakia in the 1960s. It is the C17α acetate ester of methenmadinone.
MMA given orally shows about 13-fold the progestogenic activity of parenteral progesterone in animal bioassays.
Analogues of methenmadinone acetate include methenmadinone caproate (MMC), which was studied in combination with estradiol valerate as a combined injectable contraceptive (tentative brand name Lutofollin);chlormethenmadinone acetate (chlorsuperlutin; SCH-12600; 6-chloro-MMA), which has been used in combination with mestranol in birth control pills (brand names Biogest, Sterolibrin, Antigest B) and in veterinary medicine (brand name Agelin);bromethenmadinone acetate (bromsuperlutin; 6-bromo-MMA), which was assessed but was never marketed; and melengestrol acetate (methylsuperlutin; 6-methyl-MMA), which is used in veterinary medicine.
See also
- List of progestogen esters § Esters of 17α-hydroxyprogesterone derivatives
- 16-Methylene-17α-hydroxyprogesterone acetate
| PR |
|
||||||
|---|---|---|---|---|---|---|---|
|
mPR (PAQR) |
|
||||||